Fig. 7

THOC7-AS1 ASO diminishes cSCC progression. (A) Schematic of ASO targets on THOC7-AS1. (B) THOC7-AS1, FSTL1, ZEB1, and OCT1 RNA expression after ASO treatment by qPCR in A431. (C) FSTL1, OCT1 and EMT-markers protein levels after ASO treatment. (D–E) Colony formation after ASO treatment. (F–G) Migration by scratch assay after ASO treatment. (H) Schematic of ASO treatment in xenograft model. (I) Mouse weight changes with ASO treatment. (J–L) Tumor size, weight, and volume with ASO treatment. (M) H&E and IHC for Ki67, FSTL1, ZEB1, E-cadherin, N-cadherin, and vimentin after ASO treatment, scale bars 100 μm. Data were presented as the mean ± SD. (ns, non-significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001)